<?xml version="1.0" encoding="UTF-8"?>
<p>During a primary infection the majority of antibodies are cross-reactive and non-neutralising (not protective) [
 <xref rid="B66-vaccines-07-00203" ref-type="bibr">66</xref>,
 <xref rid="B89-vaccines-07-00203" ref-type="bibr">89</xref>], most of these antibodies are anti-E antibodies against the conserved EDII fusion loop [
 <xref rid="B14-vaccines-07-00203" ref-type="bibr">14</xref>,
 <xref rid="B89-vaccines-07-00203" ref-type="bibr">89</xref>]. During secondary infection, however, anti-fusion loop antibodies are strongly neutralising [
 <xref rid="B85-vaccines-07-00203" ref-type="bibr">85</xref>]. Many of the best neutralising anti-E antibodies have been shown to bind complex epitopes dependent on the quaternary protein structure [
 <xref rid="B90-vaccines-07-00203" ref-type="bibr">90</xref>,
 <xref rid="B91-vaccines-07-00203" ref-type="bibr">91</xref>,
 <xref rid="B92-vaccines-07-00203" ref-type="bibr">92</xref>,
 <xref rid="B93-vaccines-07-00203" ref-type="bibr">93</xref>,
 <xref rid="B94-vaccines-07-00203" ref-type="bibr">94</xref>]. Included within this are antibodies that interact with the fusion loop [
 <xref rid="B90-vaccines-07-00203" ref-type="bibr">90</xref>,
 <xref rid="B91-vaccines-07-00203" ref-type="bibr">91</xref>,
 <xref rid="B92-vaccines-07-00203" ref-type="bibr">92</xref>,
 <xref rid="B93-vaccines-07-00203" ref-type="bibr">93</xref>,
 <xref rid="B94-vaccines-07-00203" ref-type="bibr">94</xref>].
</p>
